• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阴道微生物组的多样性可预测局部晚期宫颈癌新辅助化疗的反应性。

The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer.

机构信息

Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出版信息

Microb Ecol. 2022 Jul;84(1):302-313. doi: 10.1007/s00248-021-01800-0. Epub 2021 Aug 17.

DOI:10.1007/s00248-021-01800-0
PMID:34405250
Abstract

The vaginal microbiota is closely related to HPV infection and cervical cancer (CC), but its relationship with platinum-based chemotherapy responsiveness is unknown. The study aimed to investigate the vaginal microbiota diversity of women with locally advanced cervical cancer (LACC) and compare the differences between responders and nonresponders. We characterized the 16S rRNA gene sequencing of vaginal microbiome of 66 vaginal samples, including 26 LACC patients before neoadjuvant chemotherapy and 40 healthy controls. Compared with the healthy controls, alpha diversity was significantly increased in CC patients (p <0.05) with more unconventionality bacterial colonization. Beta diversity also significantly differed between cervical cancer patients and controls (p <0.01). Within the CC patients, alpha diversity in vaginal samples was significantly higher in the nonresponders versus the responders (p <0.01), and the Ace index and Chao index were negatively correlated with mass reduction (p <0.001). Moreover, the Bacteroides genus enriched in the nonresponders had a ROC-plot AUC value reaching 0.84. The study suggests the vaginal microbiota in LACC patients is associated with platinum-based chemotherapy responsiveness. Alpha diversity and Bacteroides abundance have the potential of identifying platinum-resistant patients at an early time. These findings provide a basis for further research on the relationship between vaginal microbiome and chemotherapy effect in LACC.

摘要

阴道微生物群与 HPV 感染和宫颈癌(CC)密切相关,但与铂类化疗反应性的关系尚不清楚。本研究旨在调查局部晚期宫颈癌(LACC)女性的阴道微生物群多样性,并比较反应者和非反应者之间的差异。我们对 66 个阴道样本的 16S rRNA 基因测序进行了特征分析,其中包括 26 名接受新辅助化疗前的 LACC 患者和 40 名健康对照。与健康对照组相比,CC 患者的 alpha 多样性显着增加(p<0.05),非常规细菌定植更多。beta 多样性也在宫颈癌患者和对照组之间存在显着差异(p<0.01)。在 CC 患者中,非反应者的阴道样本 alpha 多样性显着高于反应者(p<0.01),Ace 指数和 Chao 指数与质量减少呈负相关(p<0.001)。此外,非反应者中富集的拟杆菌属具有达到 0.84 的 ROC 曲线 AUC 值。本研究表明,LACC 患者的阴道微生物群与铂类化疗反应性有关。alpha 多样性和拟杆菌属丰度有可能在早期识别出铂类耐药患者。这些发现为进一步研究 LACC 中阴道微生物群与化疗效果之间的关系提供了基础。

相似文献

1
The Diversity of Vaginal Microbiota Predicts Neoadjuvant Chemotherapy Responsiveness in Locally Advanced Cervical Cancer.阴道微生物组的多样性可预测局部晚期宫颈癌新辅助化疗的反应性。
Microb Ecol. 2022 Jul;84(1):302-313. doi: 10.1007/s00248-021-01800-0. Epub 2021 Aug 17.
2
Relationship between vaginal and oral microbiome in patients of human papillomavirus (HPV) infection and cervical cancer.HPV 感染及宫颈癌患者的阴道和口腔微生物组的关系。
J Transl Med. 2024 Apr 29;22(1):396. doi: 10.1186/s12967-024-05124-8.
3
Altered microbial diversity and composition of multiple mucosal organs in cervical cancer patients.宫颈癌患者多个黏膜器官微生物多样性和组成的改变。
BMC Cancer. 2024 Sep 17;24(1):1154. doi: 10.1186/s12885-024-12915-1.
4
[Primary study on the relationship between high-risk HPV infection and vaginal cervical microbiota].[高危型人乳头瘤病毒感染与阴道宫颈微生物群关系的初步研究]
Zhonghua Fu Chan Ke Za Zhi. 2018 Jul 25;53(7):471-480. doi: 10.3760/cma.j.issn.0529-567x.2018.07.006.
5
Exploring the diversity of vaginal microbiota between healthy women and cervical cancer patients in India.探讨印度健康女性和宫颈癌患者阴道微生物群的多样性。
J Med Microbiol. 2024 Mar;73(3). doi: 10.1099/jmm.0.001819.
6
Leveraging existing 16S rRNA gene surveys to decipher microbial signatures and dysbiosis in cervical carcinogenesis.利用现有的 16S rRNA 基因调查来破译宫颈癌变中的微生物特征和失调。
Sci Rep. 2024 May 21;14(1):11532. doi: 10.1038/s41598-024-62531-z.
7
Distinction between vaginal and cervical microbiota in high-risk human papilloma virus-infected women in China.中国高危型人乳头瘤病毒感染女性阴道和宫颈微生物群的区别。
BMC Microbiol. 2021 Mar 25;21(1):90. doi: 10.1186/s12866-021-02152-y.
8
Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls.宫颈癌患者与健康对照者的肠道微生物多样性和属水平差异。
Gynecol Oncol. 2019 Nov;155(2):237-244. doi: 10.1016/j.ygyno.2019.09.002. Epub 2019 Sep 26.
9
Changes in vaginal microbiome after focused ultrasound treatment of high-risk human papillomavirus infection-related low-grade cervical lesions.聚焦超声治疗高危型人乳头瘤病毒感染相关低度宫颈病变后阴道微生物组的变化。
BMC Infect Dis. 2023 Jan 5;23(1):3. doi: 10.1186/s12879-022-07937-8.
10
Vaginal microecological changes of different degrees of cervical lesions in Hakka women in Meizhou City.梅州市客家妇女不同程度宫颈病变的阴道微生态变化。
J Obstet Gynaecol. 2023 Dec;43(1):2186780. doi: 10.1080/01443615.2023.2186780.

引用本文的文献

1
Role of Vaginal and Gut Microbiota in Human Papillomavirus (HPV) Progression and Cervical Cancer: A Systematic Review of Microbial Diversity and Probiotic Interventions.阴道和肠道微生物群在人乳头瘤病毒(HPV)进展及宫颈癌中的作用:微生物多样性与益生菌干预的系统评价
Cureus. 2025 Jun 12;17(6):e85880. doi: 10.7759/cureus.85880. eCollection 2025 Jun.
2
The Interplay Between Cervicovaginal Microbiota Diversity, Profiles and Human Papillomavirus in Cervical Cancer: A Systematic Review.宫颈癌中宫颈阴道微生物群多样性、特征与人类乳头瘤病毒之间的相互作用:一项系统评价
Healthcare (Basel). 2025 Mar 10;13(6):599. doi: 10.3390/healthcare13060599.
3

本文引用的文献

1
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.2018 年宫颈癌发病率和死亡率的估计:全球分析。
Lancet Glob Health. 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. Epub 2019 Dec 4.
2
Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls.宫颈癌患者与健康对照者的肠道微生物多样性和属水平差异。
Gynecol Oncol. 2019 Nov;155(2):237-244. doi: 10.1016/j.ygyno.2019.09.002. Epub 2019 Sep 26.
3
A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer.
Associations of the gut, cervical, and vaginal microbiota with cervical cancer: a systematic review and meta-analysis.
肠道、宫颈和阴道微生物群与宫颈癌的关联:一项系统综述和荟萃分析。
BMC Womens Health. 2025 Feb 15;25(1):65. doi: 10.1186/s12905-025-03599-1.
4
Brachytherapy for cervical cancer: from intracavitary to interstitial technique.宫颈癌近距离治疗:从腔内技术到组织间插植技术。
Front Oncol. 2024 Nov 6;14:1442712. doi: 10.3389/fonc.2024.1442712. eCollection 2024.
5
The intra-tumoral microbiome as a potential biomarker of response to external beam radiation therapy in cervical cancer.肿瘤内微生物组作为宫颈癌对外照射反应的潜在生物标志物。
J Transl Med. 2024 Oct 28;22(1):972. doi: 10.1186/s12967-024-05774-8.
6
Vaginal microbial profile of cervical cancer patients receiving chemoradiotherapy: the potential involvement of Lactobacillus iners in recurrence.宫颈癌放化疗患者阴道微生物特征:内氏乳杆菌在复发中的潜在作用。
J Transl Med. 2024 Jun 17;22(1):575. doi: 10.1186/s12967-024-05332-2.
7
Leveraging existing 16S rRNA gene surveys to decipher microbial signatures and dysbiosis in cervical carcinogenesis.利用现有的 16S rRNA 基因调查来破译宫颈癌变中的微生物特征和失调。
Sci Rep. 2024 May 21;14(1):11532. doi: 10.1038/s41598-024-62531-z.
8
Cervicovaginal microbiota: a promising direction for prevention and treatment in cervical cancer.宫颈阴道微生物群:宫颈癌预防与治疗的一个有前景的方向。
Infect Agent Cancer. 2024 Apr 19;19(1):13. doi: 10.1186/s13027-024-00573-8.
9
Highly specific vaginal microbiome signature for gynecological cancers.妇科癌症高度特异性的阴道微生物群特征。
Open Life Sci. 2024 Apr 16;19(1):20220850. doi: 10.1515/biol-2022-0850. eCollection 2024.
10
Unraveling the Dysbiosis of Vaginal Microbiome to Understand Cervical Cancer Disease Etiology-An Explainable AI Approach.解析阴道微生物组失调以了解宫颈癌发病机制——一种可解释的人工智能方法。
Genes (Basel). 2023 Apr 18;14(4):936. doi: 10.3390/genes14040936.
一项关于益生菌对降低胃癌患者因部分胃切除引起的生理和微生物紊乱严重程度的随机试验。
J Cancer. 2019 Jan 1;10(3):568-576. doi: 10.7150/jca.29072. eCollection 2019.
4
Correlation between the diversity of vaginal microbiota and the risk of high-risk human papillomavirus infection.阴道微生物多样性与高危型人乳头瘤病毒感染风险的相关性。
Int J Gynecol Cancer. 2019 Jan;29(1):28-34. doi: 10.1136/ijgc-2018-000032.
5
Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis.微生物群失调与HPV诱导的宫颈癌发生有关。
Oncol Lett. 2018 Dec;16(6):7035-7047. doi: 10.3892/ol.2018.9509. Epub 2018 Sep 26.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
The management of locally advanced cervical cancer.局部晚期宫颈癌的管理。
Curr Opin Oncol. 2018 Sep;30(5):323-329. doi: 10.1097/CCO.0000000000000471.
8
Association Between Bacteremia From Specific Microbes and Subsequent Diagnosis of Colorectal Cancer.特定微生物引起的菌血症与随后结直肠癌诊断的相关性。
Gastroenterology. 2018 Aug;155(2):383-390.e8. doi: 10.1053/j.gastro.2018.04.028. Epub 2018 May 3.
9
Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.微生物群-药物相互作用:对治疗药物代谢和疗效的影响。
Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012. Epub 2018 Apr 5.
10
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.肠道微生物组对癌症、免疫和癌症免疫治疗的影响。
Cancer Cell. 2018 Apr 9;33(4):570-580. doi: 10.1016/j.ccell.2018.03.015.